Robert W. Baird Issues Pessimistic Forecast for Twist Bioscience (NASDAQ:TWST) Stock Price

Twist Bioscience (NASDAQ:TWST) had its price target lowered by equities research analysts at Robert W. Baird from $54.00 to $44.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Robert W. Baird’s price target would suggest a potential upside of 22.46% from the company’s previous close.

TWST has been the subject of a number of other research reports. Guggenheim set a $50.00 price target on shares of Twist Bioscience in a research note on Friday, March 28th. Barclays decreased their target price on shares of Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating for the company in a research note on Thursday, April 10th. Scotiabank restated an “outperform” rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. Finally, JPMorgan Chase & Co. cut their price target on Twist Bioscience from $40.00 to $33.00 and set an “underweight” rating for the company in a research note on Tuesday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, Twist Bioscience has a consensus rating of “Moderate Buy” and an average target price of $51.10.

Twist Bioscience Price Performance

Shares of TWST opened at $35.93 on Tuesday. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. The firm’s fifty day simple moving average is $39.13 and its 200-day simple moving average is $43.98. The firm has a market capitalization of $2.14 billion, a price-to-earnings ratio of -10.63 and a beta of 2.54. Twist Bioscience has a twelve month low of $33.16 and a twelve month high of $60.90.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Monday, May 5th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.10). Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company had revenue of $92.79 million for the quarter, compared to analyst estimates of $92.00 million. Equities analysts forecast that Twist Bioscience will post -2.12 EPS for the current fiscal year.

Insider Buying and Selling at Twist Bioscience

In related news, COO Patrick John Finn sold 2,058 shares of Twist Bioscience stock in a transaction dated Wednesday, April 23rd. The stock was sold at an average price of $39.99, for a total value of $82,299.42. Following the completion of the transaction, the chief operating officer now directly owns 265,460 shares in the company, valued at approximately $10,615,745.40. This trade represents a 0.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Robert Chess sold 2,940 shares of the business’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $53.13, for a total value of $156,202.20. Following the completion of the sale, the director now owns 18,173 shares of the company’s stock, valued at $965,531.49. This trade represents a 13.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 12,137 shares of company stock valued at $530,112 in the last three months. Corporate insiders own 3.01% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Arizona State Retirement System lifted its stake in shares of Twist Bioscience by 1.3% in the 4th quarter. Arizona State Retirement System now owns 16,985 shares of the company’s stock worth $789,000 after acquiring an additional 219 shares during the period. Van ECK Associates Corp lifted its holdings in shares of Twist Bioscience by 56.4% during the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock valued at $34,000 after purchasing an additional 267 shares during the last quarter. Hillsdale Investment Management Inc. increased its position in shares of Twist Bioscience by 0.4% in the fourth quarter. Hillsdale Investment Management Inc. now owns 78,000 shares of the company’s stock worth $3,625,000 after acquiring an additional 300 shares in the last quarter. GAMMA Investing LLC raised its stake in Twist Bioscience by 68.1% during the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock valued at $29,000 after purchasing an additional 303 shares during the period. Finally, Deerfield Management Company L.P. Series C increased its holdings in shares of Twist Bioscience by 1.7% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 23,827 shares of the company’s stock valued at $1,107,000 after purchasing an additional 403 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.